To determine the impact of tuberculosis (TB) treatment at the time of combination antiretroviral therapy (cART) initiation on virologic and CD4+ cell count response to cART.
Systematic review and meta-analysis of studies reporting HIV RNA and CD4+ cell count response, stratified by TB treatment status at cART initiation. Stratified random-effects and meta-regression analyses were used when possible.
Twenty-five eligible cohort studies reported data on 49 578 (range 42–15 646) adults, of whom 8826 (18%) were receiving TB treatment at cART initiation. Seventeen studies reported virologic response; 21 reported CD4+ cell count response. The summarized random-effects relative risk (RRRE) of virologic suppression in those receiving vs. not receiving TB treatment at different time points following cART initiation was 1.06 (0.86–1.29) at 1–4 months, 0.91 (0.83–1.00) at 6 months, 0.99 (0.94–1.05) at 11–12 months, and 0.99 (0.77–1.28) at 18–48 months. The overall RRRE at 1–48 months was 0.97 (95% confidence interval 0.92–1.03). Available data regarding the effect of TB treatment on virologic failure were heterogeneous and inconclusive (13 estimates). Differences in median CD4+ cell count gain between those receiving vs. not receiving TB treatment ranged from −10 to 60 cells/μl (median 27) by 6 months (seven estimates) and −10 to 29 (median 6) by 11–12 months (five estimates), although the heterogeneity of the response measures did not support meta-analysis.
Patients receiving TB treatment at cART initiation experience similar virologic suppression and CD4+ cell count reconstitution as those not receiving TB treatment, reinforcing the need to start cART during TB treatment and allowing more confidence in clinical decision-making.
aDepartment of Epidemiology
bDivision of Infectious Diseases
cCenter for AIDS Research, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Correspondence to Heidi M. Soeters, Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, 2101 McGavran-Greenberg Hall, CB #7435, Chapel Hill, NC 27599-7435, USA. Tel: +1 404 308 1200; e-mail: firstname.lastname@example.org
Received 3 July, 2013
Accepted 14 July, 2013
Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Website (http://www.AIDSonline.com).